Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study

Autor: Daudén, E, Griffiths, Cem, Ortonne, J-P, Kragballe, K, Molta, Ct, Robertson, D, Pedersen, R, Estojak, J, Boggs, R

Publikováno v: Daudén, E, Griffiths, C, Ortonne, J-P, Kragballe, K, Molta, C, Robertson, D, Pedersen, R, Estojak, J & Boggs, R 2009, ' Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study ', Journal of the European Academy of Dermatology and Venereology . https://doi.org/10.1111/j.1468-3083.2009.03321.x

Udgivelsesdato: 2009-Jun-26 Objective To assess patient-reported outcomes (PRO) in patients with moderate-to-severe plaque psoriasis receiving continuous or paused etanercept treatment. Methods In a multicentre European open-label study, one group (n

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pure_au_____::cbad2098cea49c061869d7d69aca4972
https://pure.au.dk/portal/da/publications/improvements-in-patientreported-outcomes-in-moderatetosevere-psoriasis-patients-receiving-continuous-or-paused-etanercept-treatment-over-54-weeks-the-crystel-study(55d691e0-978a-11de-a092-000ea68e967b).html

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Factors associated with physicians' prescriptions for rheumatoid arthritis drugs not filled by patients.

Autor: Kan HJ; Center for Population Health IT, Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Hampton House HH502, 624 N. Broadway, Baltimore, MD, 21205, USA. hkan1@jhu.edu., Dyagilev K; Cortica US, 425 Broadway, New York, NY, 10013, USA., Schulam P; Computer Science Department, Johns Hopkins University, 3400 N Charles Sreett, Baltimore, MD, 21218, USA., Saria S; Computer Science Department, Johns Hopkins University, 3400 N Charles Sreett, Baltimore, MD, 21218, USA., Kharrazi H; Center for Population Health IT, Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Hampton House HH502, 624 N. Broadway, Baltimore, MD, 21205, USA., Bodycombe D; Center for Population Health IT, Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Hampton House HH502, 624 N. Broadway, Baltimore, MD, 21205, USA., Molta CT; Main Line Rheumatology, Lankenau Medical Center, 100 Lancaster Avenue, Wynnewood, PA, 19096, USA., Curtis JR; Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, 510 20th Street South, Birmingham, AL, 35294, USA.

Publikováno v: Arthritis research & therapy [Arthritis Res Ther] 2018 May 02; Vol. 20 (1), pp. 79. Date of Electronic Publication: 2018 May 02.

Cumulative Corticosteroid Dose Over Fifty-Two Weeks in Patients With Systemic Lupus Erythematosus: Pooled Analyses From the Phase III Belimumab Trials.

Autor: van Vollenhoven RF; Academic Medical Center, Amsterdam, The Netherlands., Petri M; Johns Hopkins University School of Medicine, Baltimore, Maryland., Wallace DJ; Cedars-Sinai Medical Center and University of California, Los Angeles David Geffen School of Medicine, Los Angeles., Roth DA; GlaxoSmithKline, Research Triangle Park, North Carolina., Molta CT; GlaxoSmithKline, Philadelphia, Pennsylvania., Hammer AE; GlaxoSmithKline, Research Triangle Park, North Carolina., Tang Y; GlaxoSmithKline, Research Triangle Park, North Carolina., Thompson A; GlaxoSmithKline, Research Triangle Park, North Carolina.

Publikováno v: Arthritis & rheumatology (Hoboken, N.J.) [Arthritis Rheumatol] 2016 Sep; Vol. 68 (9), pp. 2184-92.

Post-marketing experiences with belimumab in the treatment of SLE patients.

Autor: Askanase AD; Department of Medicine, Columbia University Medical Center, 630 West 168th Street, P&S 10-508, New York, NY 10032, USA. Electronic address: ada20@columbia.edu., Yazdany J; Department of Medicine, University of California, San Francisco, School of Medicine, 1001 Potrero Avenue, SFGH 30, San Francisco, CA 94143, USA., Molta CT; GlaxoSmithKline, 5 Crescent Drive, Philadelphia, PA 10112, USA.

Publikováno v: Rheumatic diseases clinics of North America [Rheum Dis Clin North Am] 2014 Aug; Vol. 40 (3), pp. 507-17, viii. Date of Electronic Publication: 2014 Jun 03.